Hybio Pharmaceutical Co., Ltd. (SHE:300199)

Market Cap	19.31B -1.9%
Revenue (ttm)	1.53B +69.9%
Net Income	401.86M
EPS	0.44
Shares Out	883.24M
PE Ratio	49.70
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,645,702
Open	24.34
Previous Close	22.31
Day's Range	21.02 - 24.34
52-Week Range	16.23 - 27.70
Beta	0.69
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About Hybio Pharmaceutical

Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of pharmaceutical products in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as medical devices comprising disposable injectable pens; and peptide active pharmaceutical ingredients (API) comprising polypeptides, small molecules and nucleic acid...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 1,226
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300199

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 30, 2026

Data Sources Report a data error